📊 INNV Key Takeaways
Is INNV a Good Investment? Thesis Analysis
InnovAge demonstrates solid revenue growth (11.8% YoY) with improving net income (+14.2% YoY), supported by strong free cash flow generation and a fortress balance sheet with low leverage. However, thin profitability margins (3.9% net margin) and significant EPS decline (-37.5% YoY despite higher earnings) suggest dilution concerns that warrant caution despite fundamentally improving operations.
Why Buy INNV? Key Strengths
- Strong revenue growth of 11.8% YoY indicating market demand in healthcare services
- Robust free cash flow of $18.8M with 4.0% FCF margin demonstrating operational efficiency
- Conservative balance sheet with low debt-to-equity ratio of 0.22x and healthy interest coverage of 8.2x
- Positive net income growth of 14.2% YoY outpacing revenue growth suggests improving operational leverage
- Adequate liquidity with current ratio of 1.26x and $83.2M cash position
INNV Investment Risks to Consider
- Severely diluted EPS (-37.5% YoY) despite higher net income indicates significant share issuance that erodes shareholder value
- Thin net profit margin of 3.9% and low operating margin of 4.5% leave minimal room for error in healthcare services sector
- Low ROE (7.3%) and ROA (3.5%) suggest inefficient capital deployment relative to equity and asset base
- No insider buying activity in last 90 days may indicate management's lack of confidence in current valuation or outlook
- Modest gross margin of 21.9% typical of healthcare services may face compression from rising labor and operational costs
Key Metrics to Watch
- Operating margin expansion and ability to maintain pricing power as healthcare labor costs rise
- Share dilution rate and pattern of equity issuance relative to FCF generation
- Revenue growth sustainability beyond 11.8% and market share gains in PACE and home health segments
- FCF conversion ratio and capital efficiency metrics to assess quality of earnings growth
- Debt levels and refinancing needs given modest operating margins in cyclical healthcare environment
INNV Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.0% FCF margin may limit capital allocation flexibility.
INNV Profitability Ratios
INNV vs Default Sector
How InnovAge Holding Corp. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INNV Overvalued or Undervalued?
Based on fundamental analysis, InnovAge Holding Corp. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INNV Balance Sheet & Liquidity
INNV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: InnovAge Holding Corp.'s revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
INNV Growth Metrics (YoY)
INNV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $209.0M | $10.6M | $0.08 |
| Q1 2026 | $205.1M | -$4.9M | $-0.04 |
| Q3 2025 | $193.1M | -$5.9M | $-0.04 |
| Q2 2025 | $188.9M | -$3.4M | $-0.03 |
| Q1 2025 | $182.5M | -$4.9M | $-0.04 |
| Q3 2024 | $172.5M | -$5.9M | $-0.04 |
| Q2 2024 | $167.5M | -$3.4M | $-0.03 |
| Q1 2024 | $171.2M | -$10.3M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INNV Capital Allocation
INNV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for InnovAge Holding Corp. (CIK: 0001834376)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INNV
What is the AI rating for INNV?
InnovAge Holding Corp. (INNV) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INNV's key strengths?
Claude: Strong revenue growth of 11.8% YoY indicating market demand in healthcare services. Robust free cash flow of $18.8M with 4.0% FCF margin demonstrating operational efficiency.
What are the risks of investing in INNV?
Claude: Severely diluted EPS (-37.5% YoY) despite higher net income indicates significant share issuance that erodes shareholder value. Thin net profit margin of 3.9% and low operating margin of 4.5% leave minimal room for error in healthcare services sector.
What is INNV's revenue and growth?
InnovAge Holding Corp. reported revenue of $475.8M.
Does INNV pay dividends?
InnovAge Holding Corp. pays dividends, with $9.5M distributed to shareholders in the trailing twelve months.
Where can I find INNV SEC filings?
Official SEC filings for InnovAge Holding Corp. (CIK: 0001834376) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INNV's EPS?
InnovAge Holding Corp. has a diluted EPS of $0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INNV a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, InnovAge Holding Corp. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INNV stock overvalued or undervalued?
Valuation metrics for INNV: ROE of 7.3% (sector avg: 15%), net margin of 3.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INNV stock in 2026?
Our dual AI analysis gives InnovAge Holding Corp. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INNV's free cash flow?
InnovAge Holding Corp.'s operating cash flow is $25.3M, with capital expenditures of $6.4M. FCF margin is 4.0%.
How does INNV compare to other Default stocks?
Vs Default sector averages: Net margin 3.9% (avg: 12%), ROE 7.3% (avg: 15%), current ratio 1.26 (avg: 1.8).